JW Therapeutics: JW Therapeutics' Carteyva receives breakthrough therapy status for r/r LBCL

This designation is for Carteyva, an anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy, as a second-line treatment for adults with this disease. It is developed independently The post JW Therapeutics' Carteyva receives breakthrough therapy status for r/r LBCL appeared first on Pharmaceutical Business review.